Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for NAION
RecruitingPhase 1
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for the Treatment of Non-arteritic Ischemic Optic Neuropathy
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion Criteria: * Diagnosis of NAION (non-arteritic ischemic optic neuropathy) * Understanding and willingness to sign a written informed consent document Exclusion Criteria: * Active infection * Active cancer * Chronic multisystem organ failure * Pregnancy * Clinically significant Abnormalities on pre-treatment laboratory evaluation * Medical condition that would (based on the opinion of the investigator) compromise patient's safety. * Continued drug abuse * Pre-menopausal women not using contraception * Previous organ transplant * Hypersensitivity to sulfur
About the study
This trial will study the safety and efficacy of intranasal delivery of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes for the treatment of non-arteritic ischemic optic neuropathy
What is being tested
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes (biological)
Sponsor: The Foundation for Orthopaedics and Regenerative Medicine · Participants: 20 · Started: Feb 1, 2022
Contact the study team
- Chadwick Prodromos, MD · Phone: 847-699-6810
Official record on ClinicalTrials.gov — NCT05147701
Locations in the U.S.
| Florida | Prodromos Stem Cell Institute, Naples |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.